These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 15963657)

  • 41. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice.
    Hodgetts S; Radley H; Davies M; Grounds MD
    Neuromuscul Disord; 2006 Oct; 16(9-10):591-602. PubMed ID: 16935507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antitumor triptycene analogs directly interact with isolated mitochondria to rapidly trigger markers of permeability transition.
    Perchellet EM; Wang Y; Lou K; Zhao H; Battina SK; Hua DH; Perchellet JP
    Anticancer Res; 2007; 27(5A):3259-71. PubMed ID: 17970069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel mitochondrial tRNA Leu(CUN) transition and D4Z4 partial deletion in a patient with a facioscapulohumeral phenotype.
    Filosto M; Tonin P; Scarpelli M; Savio C; Greco F; Mancuso M; Vattemi G; Govoni V; Rizzuto N; Tupler R; Tomelleri G
    Neuromuscul Disord; 2008 Mar; 18(3):204-9. PubMed ID: 18343111
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ca2+ sparks as a plastic signal for skeletal muscle health, aging, and dystrophy.
    Weisleder N; Ma JJ
    Acta Pharmacol Sin; 2006 Jul; 27(7):791-8. PubMed ID: 16787561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of creatine and exercise on skeletal muscle of FRG1-transgenic mice.
    Ogborn DI; Smith KJ; Crane JD; Safdar A; Hettinga BP; Tupler R; Tarnopolsky MA
    Can J Neurol Sci; 2012 Mar; 39(2):225-31. PubMed ID: 22343158
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy.
    Bertorini TE; Palmieri GM; Griffin JW; Igarashi M; McGee J; Brown R; Nutting DF; Hinton AB; Karas JG
    Neurology; 1988 Apr; 38(4):609-13. PubMed ID: 3281058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Total Hip Arthroplasty in a Patient With Fascioscapulohumeral Dystrophy.
    Thomas RA; Warfield DJ; Nikkel LE
    Arthroplast Today; 2023 Feb; 19():101021. PubMed ID: 36845289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rethinking the genetic basis and inheritance of fascioscapulohumeral muscular dystrophy.
    Hawkins AK
    Clin Genet; 2012 Sep; 82(3):219-20. PubMed ID: 22697186
    [No Abstract]   [Full Text] [Related]  

  • 49. SYNTHETIC ALPHA-TOCOPHEROL AND NUTRITIONAL MUSCULAR DYSTROPHY.
    Morris SG
    Science; 1939 Nov; 90(2340):424-5. PubMed ID: 17834136
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD): A Systematic Review.
    Aguirre AS; Astudillo Moncayo OM; Mosquera J; Muyolema Arce VE; Gallegos C; Ortiz JF; Andrade AF; Oña S; Buj MJ
    Cureus; 2023 Jun; 15(6):e39903. PubMed ID: 37404420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Purification and Biological Function of Caldecrin.
    Tomomura A; Bandow K; Tomomura M
    Medicines (Basel); 2021 Jul; 8(8):. PubMed ID: 34436220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
    Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
    Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Facioscapulohumeral Muscular Dystrophy.
    Statland JM; Tawil R
    Continuum (Minneap Minn); 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):1916-1931. PubMed ID: 27922500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. β-Catenin is central to DUX4-driven network rewiring in facioscapulohumeral muscular dystrophy.
    Banerji CR; Knopp P; Moyle LA; Severini S; Orrell RW; Teschendorff AE; Zammit PS
    J R Soc Interface; 2015 Jan; 12(102):20140797. PubMed ID: 25551153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Altered expression of cyclin A 1 in muscle of patients with facioscapulohumeral muscle dystrophy (FSHD-1).
    Pakula A; Schneider J; Janke J; Zacharias U; Schulz H; Hübner N; Mähler A; Spuler A; Spuler S; Carlier P; Boschmann M
    PLoS One; 2013; 8(9):e73573. PubMed ID: 24019929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of facioscapulohumeral muscular dystrophy with Denosumab.
    Lefkowitz SS; Lefkowitz DL; Kethley J
    Am J Case Rep; 2012; 13():66-8. PubMed ID: 23569491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fascioscapulohumeral muscular dystrophy: a progressive degenerative disease that responds to diltiazem.
    Lefkowitz DL; Lefkowitz SS
    Med Hypotheses; 2005; 65(4):716-21. PubMed ID: 15963657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RAGE-NF-kappaB pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy.
    Macaione V; Aguennouz M; Rodolico C; Mazzeo A; Patti A; Cannistraci E; Colantone L; Di Giorgio RM; De Luca G; Vita G
    Acta Neurol Scand; 2007 Feb; 115(2):115-21. PubMed ID: 17212615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The adenine nucleotide translocase type 1 (ANT1): a new factor in mitochondrial disease.
    Sharer JD
    IUBMB Life; 2005 Sep; 57(9):607-14. PubMed ID: 16203679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy.
    Osborne RJ; Welle S; Venance SL; Thornton CA; Tawil R
    Neurology; 2007 Feb; 68(8):569-77. PubMed ID: 17151338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.